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To my family for their endless love and support. 
"Hay dias en que somos tan moviles, tan moviles, 
como las leves briznas al viento y al azar... 
Tal vez bajo otro cielo la Gloria nos sonria... 
La vida es clara, undivaga, y abierta como un mar... 
Y hay dias en que somos tan fertiles, tan fertiles, 
como en Abril el campo, que tiembla de pasion; 
bajo el influjo provido de espirituales lluvias, 
el alma esta brotando florestas de ilusion. 
Y hay dias en que somos tan sordidos, tan sordidos, 
como la entrana obscura de obscuro pedernal; 
la noche nos sorprende, con sus profusas lamparas, 
en rutilas monedas tasando el Bien y el Mai. 
Y hay dias en que somos tan placidos, tan placidos... 
-jninez en el crepusculo! jlagunas de zafir!-
que un verso, un trino, un monte, un pajaro que cruza, 
iy hasta las propias penas! nos hacen sonreir... 
Y hay dias en que somos tan lubricos, tan lubricos, 
que nos depara en vano su carne la mujer; 
tras de cenir un talle y acariciar un seno, 
la redondez de un fruto nos vuelve a estremecer. 
Y hay dias en que somos tan lugubres, tan lugubres, 
como en las noches lugubres el llanto del pinar: 
el alma gime entonces bajo el dolor del mundo, 
y acaso ni Dios mismo nos pueda consolar. 
Mas hay tambien joh Tierra! un dia... un dia... un dia 
en que levamos anclas para jamas volver; 
un dia en que discurren vientos ineluctables... 
jUn dia en que ya nadie nos puede retener!" 
(Porfirio Barba Jacob) 
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ABSTRACT 
SYNTHESIS OF 1,4,7-TRIAZACYCLONONANE PENDANT-ARMED 
CHELATORS AND THEIR METAL COMPLEXES 
by 
Elizabeth Garcia Cardona 
University of New Hampshire, December, 2010 
Pendant-armed cyclic polyamines have been demonstrated to be promising 
ligands for the development of new metal-based radiopharmaceuticals for positron-
emission tomography (PET). Macrocyclic polyamines bearing pendant arms can 
effectively bind specific metals with suitable complexation kinetics and stability while 
attached to a tumor-targeting vector or peptide. 64Cu-radiolabeled peptides containing the 
chelator 1,4,7-triazacyclononane 1,4,7-triacetate have been shown to possess superior 
properties which overcome commonly observed problems such as demetallation and 
accumulation of the radio-metal in non-targeted tissues. To model these radiolabeled 
bioconjugates and to gain insight into this observed bio-stability, the synthesis of a 
copper (II) complex of a new triazacyclononane derivative containing one amide and two 
acetate groups (NOAM2A) has been performed. Studies of its acid inertness and 
electrochemistry behavior have been investigated. Complementary, copper (II) 




1.1 1, 4, 7- Triazacyclononane and Related Triazamacrocyclic Compounds 
The use of cyclic polyamine compounds as ligands for metal complexation has 
due in part to their relevance in bioinorganic and catalytic studies, as well as their 
applications in biology, medicine, and modern clinical imaging protocols.1"5 
Cyclic polyamine compounds include a large group of polydentate ligands 
containing nitrogen donor atoms within a ring.2 1,4,7-Triazacyclononane (1) (TACN) 
contains nine atoms of which three are nitrogen and it is the parent of a family of ligands 
which have been used for the complexation of a myriad of metals. This tridentate ligand 
has three-fold symmetry (Figure 1.01) and usually occupies one hemisphere of the metal 
coordination sphere.1 
expanded over the years.1"4 Interest in the coordination chemistry of these chelators is 




Figure 1.01: 1,4,7-triazacyclononane 
1 
The synthesis of TACN was reported by Koyama and Yoshino in 1972.6 TACN 
was obtained from its precursor, 1 -4-di-/?-toluenesulfonyl-1 -4-7-triazacyclononane, via 
hydrolysis of the tosylamide groups with hydrobromic acid and glacial acetic acid.6 The 
synthesis of its precursor had been reported in 1937 in a very low yield, 18%, thus it was 
not ideal.7 Other approaches towards the synthesis of cyclic tosylamines were reported by 
Stetter and Roos. Condensation of terminal dihalides with bissulfonamide sodium salts 
g 
under high dilution were performed to obtain moderate cyclization yields. In 1974, 
Richman and Atkins reported a modified and efficient method for the preparation of 9- to 
21-membered saturated macrocycles containing three to seven heteroatoms. Use of 
preformed bissulfonamide sodium salts and sulfonate ester leaving groups in a dipolar 
aprotic solvent eliminated the need of high dilution techniques, allowing preparation on a 
large scale.9 The free amine TACN is efficiently obtained by the oxidative cleavage of 
the tosyl groups with concentrated sulfuric acid at 100 °C, followed by basification of the 
tris-sulfate salt.1'9 Modified procedures have been also reported by McAuley et al.,10 
Graeme et al.,11 Sherry et al.,12 and Kellogg.13 In our group, the cyclization is performed 
using a modification of the Kellogg procedure (Scheme 1.1). 
Ts^ / \ /Ts ^ ^ / \ > < O 
HN N NH + / \ 3ME • \ / where Ts = -S—(\ /)— 
Ts Ts is T S° ° T S Cs2C°3 g ^ 
7 7 % is 
Scheme 1.1 : Protocol for the synthesis of N, N', N"-tritosyl-1,4,7-
triazacyclononane 
Following the development of a simplified synthetic approach, metal complexes 
of TACN have been extensively investigated. Early work, much of it by Wieghardt and 
coworkers, focused on the basic chemistry of TACN and were compiled in a review by 
Chaudhuri and Wieghardt.1 It was recognized that TACN is a remarkable ligand in 
supporting both mono- and bi-metallic complexes containing labile coordination sites. 
Thus, a variety of TACN complexes have been used to model both structural and 
functional metallo-enzymes.14'15 Metal complexes of the type [Metal-TACN]3+/2+ have 
been synthesized with transition and main group metals in common oxidation states. 
TACN metals complexes with Cr(III), V(IV), Mn(II), Mn(IV), Fe(III), Co(II), Co(III) 
Ni(II), Cu(II), Zn(II), Au(III), Pt(II), Pt(IV), Pd(II) Mo(II), W(II), Re(I), Ru(III), Ru(II), 
Rh(III), Os(II), Ga(III), In(III), Tl(III), Tc(II), Tc(III), and Tc(IV) have been reported in 
the literature and their coordination chemistry has been investigated by Wieghardt and 
TACN coordinates very strongly to metal ions with the metal ion above the triaza 
plane (Figure 1.02). The medium-ring size restricts its coordination to a facial manner, as 
opposed to its acyclic analogues, which can coordinate in either a facial or a meridional 
1 0 
fashion (Figure 1.03). ' The thermodynamic stabilities for most reported TACN-metal 
complexes surpass those of their open-chain analogues, this trend is also observed by 
macrocyclic molecules and it is commonly known as the macrocyclic effect stating that 
complexes of macrocyclic ligands are more stable than their acyclic 1 0 9fl 91 counterparts. ' ' ' Moreover, the medium-ring sized, TACN, has shown higher stability 
others.1A 
H 
Figure 1.02: Facial coordination mode of TACN 
3 
constants for the formation of some 1:1 ligand-metal complexes compared to the larger 
1,4,7-triazacyclodecane, 1,4,8-triazacycloundecane, and 1,5,9-triazacyclododecane 
macrocycles.1 
Figure 1.03: Facial and meridional coordination fashion in an octahedral 
complex of an acyclic triamine 
The thermodynamic stability and the kinetic inertness of coordinated 
triazamacrocyclic complexes are two important aspects that have made these ligands very 
useful in fostering advances in inorganic chemistry as well as applications in other 
scientific fields. For example biological activity data of [Au(TACN)Cl2]Cl has shown 
higher cytotoxicity than cisplatin against A-549 and HCT-116 tumor cell lines.19 To 
further optimize metal binding, this ligand system has been frequently modified by the 
attachment of pendant donor groups, typically onto nitrogens, in order to fill out 
additional metal coordination sites. 
1.1.1 /V-Functionalized Triazacyclononane Derivatives 
Attachment of functional groups (R,R',R") to the secondary amine positions in 
the medium sized ring (Figure 1.04) tunes ligand properties and enhances its 
complexation with a large variety of metal ions, providing additional control over the 
4 
ligand environment around the metals as well as overall charge. Furthermore, ligands of 
this class combine the attractive features of a chelating ring as well as faster binding 
kinetics of an open-chain. The selection of the pendant arms and their functional groups 
is based on the metal of interest, its oxidation state, and its potential applications. Gasser 
et al. reported the synthesis of a TACN derivative with two pyridyl pendant groups to 
increase its stability when complexed to copper(II) ion as compared to the parent TACN 
copper complex.22 There are many other examples of TACN derivatives with a variety of 
pendant arms shown in Table 1.01 as compounds A,23"26 B,27 C28, D, E,29F,30 G,31 H,32 
etc. One of the original and most useful N-functionalized TACN derivative is the tri-7V-
substituted N,N',N"-tris(carboxylmethyl)-14,7-triazacyclononane, NOTA, (2) 
(Figure 1.04).23 26 
R^ I \ / R 
,N N 
R=CH2COO" (2) 





H 2 C OH 













Table 1.01: Examples of TACN derivatives 
NOTA has been synthesized by reacting TACN with sodium bromoacetate and 
sodium hydroxide in aqueous solution at 80 °C as shown in Scheme 1.2.26 Its 
coordination chemistry has been studied with Ca(II), Mg(II), Al(III), Cr(III), V(IV), 
Mn(II), Mn(III), Fe(II), Fe(III), Co(II), Co(III), Ni(II), Ni(III), Cu(II), Cd(II), Pb(II), 
Ga(III), In(III), Tl(III) to form in most cases complexes of the type [M-NOTA]07"1, where 
M is one of the above metals commonly in either (II) or (III) oxidation state.1 Formation 
constants show higher stabilities in comparison to the parent TACN metal complexes 
where formation constants range from 5.8 up to 16.2 as compared to 8.8 up to 28.3 for 
NOTA complexes.1"3 
6 
0 ^ 0 Na 
H^ / \ ^H / \ J 
N N ¥ xN K y 3 BrCH2C00-Na; » / \ + 3 N a B r ( a q ) + 
' r}J- / 3NaOH,H2Oat80°C 
H (no yield reported) L ^ o 
ONa 
Scheme 1.2: Synthesis of NOTA 26 
NOTA is a potentially hexadentate ligand with a N303-donor set that has a 
favorable binding geometry for many metal complexes. The nine-membered ring 
coordinates facially to the metal ion which is enveloped simultaneously by the vV-acetate 
arms to give octahedral to trigonal prismatic geometries around the metal. 1~3'23"26'33 These 
geometries are defined by the degree of distortion from the regular octahedral 
arrangement which is given by the twist angle, 0, illustrated in Figure 1.05. Here 9 is 0° 
in a trigonal prism and 60° in a regular octahedron. 
v.0 
Trigonal prism 
0 = 0° 
Intermediate 
0° < 0 < 60° 
Octahedron 
0 = 60° 
Figure 1.05: Twist angle 
7 
The compactness of the TACN ring and the low steric requirement of the acetate 
arms lead to the formation of unusually stable metal complexes.2 The 9-membered ring, 
TACN, is chiral when coordinated to the metal ion, having a [3,3,3] conformation of the 
9 memebered ring and (888) or (XXX) conformation of the five-membered M-N-C-C-N 
chelate rings (Figure 1.06). In addition, the acetate arms on the pseudooctahedral 
complexes of NOTA can exist in two possible orientations, clockwise or 




Figure 1.06: Five-membered chelate ring conformations ,34 
O 
(858) Type I (888) Type II 
Figure 1.07: Examples of type I and type II NOTA complexes l 
8 
NOTA has been used to make complexes with an assortment of metal ions and it 
is now well-established as a useful metal chelator for many tri- and divalent transition 
metals.1'3'26 Recently, radiometal complexes of this ligand have attracted attention in 
development of new carriers for radiopharmaceutical applications. 
1.2 Radiopharmaceutical Applications 
Radiopharmaceuticals utilizing radiometal-labeled complexes is a rapidly 
growing medicinal area.35"37 Scintigraphy, single photon emission computer tomography 
(SPECT), and positron emission tomography (PET) are current imaging modalities using 
radio-metal isotopes to image a wide range of diseases including heart disease, cancer, 
brain disorders, thrombosis, kidney and liver abnormalities.38 40 
There are important factors in the selection of the proper radionuclides in 
designing radiopharmaceuticals, these include their mode of decay, energy emitted, half-
life, production methods and cost. 38-41 The half-life of the radionuclide must be long 
enough for the synthesis of the radiopharmaceutical and to allow accumulation in the 
target tissue.39"41 Among these modalities PET has advantages in terms of sensitivity and 
resolution.38'39 In these modalities, radiolabeled pharmaceuticals are injected in the body 
and imaging is obtained via detection of the decay from the targeted radioisotope inside 
the body. Different imaging modalities require pharmaceuticals with specific decay 
characteristics according to the equipment of the detection. Scintigraphy and SPECT 
require a radiopharmaceutical that possesses a gamma (y) emitting radionuclide with an 
energy range of between 100 to 250 keV. PET requires radiopharmaceuticals with a 
9 
positron-emitting (/3+) radionuclide that would eventually result in two photon emissions 
-180° apart with energy of 511 keV.39"41 
Additionally, the use of radiometals in molecular imaging applications requires 
metal ions that bind strongly to the ligands to form radionuclide complexes with kinetic 
inertness in vivo in order to prevent release of the radioisotope.42 
Copper (II) presents good characteristics as a radiometal ion for applications in 
diagnosis and therapy of disease in nuclear medicine since it provides an extensive 
selection of radioisotopes. In particular 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu can be used for 
molecular imaging and/or radiotherapy.35 These copper nuclides have half-lives ranging 
from 10 minutes up to 62 hours, and they decay by positron (/3+), electron (/3"), or gamma 
(y) emission. For instance, 64Cu has a half-life of 12.7 hours and decay of /3+=0.653 MeV 
(19%) and /T=0.579MeV (39 %). The emitted positron is ideal for PET imaging and the 
/3" suitable for targeted radiotherapy of cancer.40 Complementarily, copper has a 
well-known coordination chemistry that allows its reactions with a large number of 
ligands which can be linked to proteins, peptides, and other biologically-relevant 
molecules.40 
In order to target radiometal ions to tumors or other tissues, a bifunctional 
chelator (BFC) is required to conjugate to a peptide. This chelator should react rapidly 
enough to avoid radioactivity loss from the radiometal before injecting it to the patient. 
Structurally, it should contain a functional group for the covalent attachment of the 





•7"' lV ^ Peptide 
O ^ O 
Figure 1.08: Y-functionalized polyazamacrocyclic carboxylate-based 
bioconjugates 
Cu(II) forms complexes with azamacrocycles that have large thermodynamic 
stability constants which make them attractive for the design of radiopharmaceuticals.2'3 
These chelators provide excellent binding environments for Cu(II) ions, providing rapid 
metal complexation, and aqueous solubility.3'43 Specifically, TV-functionalized 
polyazamacrocycle carboxylate derivatives have been used in the development of 
64Cu-based imaging agents for detection and treatment of cancer. 1,4,7,10-
tetraazacyclododecane-l,4,7,10-tetraacetic acid (DOTA) (Figure 1.09) and 1,4,8,11-
tetraazacyclotetradecane-l,4,8,ll-tetraacetic acid TETA (Figure 1.09) are two important 
chelators that have been used for conjugation with peptides and radiolabeling with 64Cu 
as radioactive agents for PET.44 46 
HOOC ^ N N ^ COOH HOOC ^.N N ^ COOH ^ N ^ N ^ COOH 
H O O C \ ^ N N ^ C O O H H O O C ^ N N ^ / C O O H H O O C ^ / N N 
DOTA TETA CB-TE2A 
Figure 1.09: JV-functionalized tetraazamacrocycles DOTA, TETA and CB-TE2A 
11 
The Cu(II) complexes of DOTA and TETA have the desired high thermodynamic 
stability constants (logKcU(ii)-DOTA:=22.7 and logKcU(ii)-TETA=21.9), but unfortunately these 
are only moderately stable in vivo, resulting in significant demetallation and subsequent 
accumulation of the radiometal in nontarget tissues, decreasing the effectiveness of the 
radiopharmaceutical.3 5,47,48 
To improve the in vivo properties of the 64Cu complexes of the BFCs, researchers 
have developed and investigated other chelators. A novel family of cross-bridged 
tetraamine chelators was developed by the Weisman-Wong group49'50 and used to prepare 
64Cu-imaging agents.35'47'48 Specifically, a compound of this cross bridge class, 4,11-
bis(carboxylmethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), is a 
hexadentate ligand that forms a very stable six-coordinate Cu(II) complex by complete 
encapsulation of the metal center.50 In a collaborative effort between the Weisman-Wong 
group and the Anderson group, the efficacy of CB-TE2A in PET imaging agents was 
evaluated by conjugation to a somatostatin analogue peptide, radiolabeled with 64Cu(II), 
and its biologically activity in tumor bearing rats investigated.35'47'48 These studies 
showed reduced demetallation or accumulation of radioactivity in nontarget tissues 
observed in chelators, DOTA and TETA. 
Hoffman et al. have also reported the synthesis and characterization of a 
6 4 C U - C B - T E 2 A conjugated with bombesin (BBN), 64Cu-CB-TE2A-8-AOC-BBN(7-
14)NH2 (Figure 1.10), where BBN is a peptide able to bind to receptors that are 
expressed on a variety of human cancers and 8-AOC is the covalent linker.51 They have 
evaluated its biological activity in tumor-bearing rats and compared side by side with 
64Cu-DOTA-8-AOC-BBN(7-14)NH2 confirming superior kinetic stability of the 64Cu-
12 
CB-TE2A-8-AOC-BBN(7-14)NH2 over 64Cu-DOTA-8-AOC-BBN(7-14)NH2 with 
considerably less accumulation in non-targeted organs.51 




H ff N V A , NH2 
H o f H o 







H2N ^ O 
Figure 1.10: Chemical structure of DOTA- 8-AOC-BBN(7-14)NH2, 
CB-TE2A-8-AOC-BBN(7-14)NH2, and NOTA -8-AOC-BBN(7-14)NH251'52 53 
Hoffman and Smith have also explored the well known iV-functionalized 
trizacyclononane system, NOTA, as the BFC bioconjugated BBN as compared to DOTA-
BBN (Figure 1.10).5253 Biodistribution studies of 64Cu-NOTA-8AOC-BBN(7-14)NH2 
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have shown resistance to demetallation, accumulation and retention of the conjugate in 
renal organs while producing microPET images that are clearly superior to the 64Cu-
DOTA-conjugate.52'53 64Cu-N02A-8-A0C-BBN(7-14)NH2 gave no radioactivity in 
collateral nontarget tissues while resulting in higher target-to-nontarget accumulation 
ratios. Consequently high-quality images were obtained as compared to other 64Cu-BBN 
tracers.52'53 
CB-TE2A-8-AOC-BBN(7-14)NH2 and NOTA-8-AOC-BBN(7-14)NH2 possess 
improved in vivo properties for PET in comparison to other BFCs.51-53 At present, it is 
not well understood whether the observed properties are due to the enhanced stability 
provided by the ligand or simply the effect of superior in vivo pharmacokinetics of its 
conjugate. 
1.3 Coordination Chemistry of Copper (II) with NOTA 
The coordination chemistry of the metals must be satisfied to allow for their 
successful incorporation into a pharmaceutical. Inorganic chemistry plays an important 
role in the design of target specific radiopharmaceuticals, since it is possible to correlate 
in vivo behavior of the metal complexes to their in vitro chemical properties such as 
redox stability, charge, and solubility. 
Complexes of NOTA with Cu(II) were first reported by Hama and Takamoto and 
later structurally characterized by Wieghardt and Hancock. ' ' Two different 
coordination modes have been described. First, Wieghardt reported that the central 
copper(II) ion is six-coordinated to three nitrogens and three oxygens of the hexadentate 
ligand. The structure consists of the anionic unit [Cu(II)-NOTA]~ with Na+ as counter ion 
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(Figure 1.11), where the donor atoms are disposed in a bifacial arrangement. Three N 
ring atoms occupy one facial plane while three carboxylate O atoms form the other plane. 
A twist angle, 0, between 26-27° indicates an intermediate geometry between a 
octahedral and a prismatic geometry of the Cu(II)N303 coordination sphere. 
Na1" [Cu(II)-NOT A]" [CuCl-NOTA-H2] 
Figure 1.11: Two different structures for Cu-NOTA 
Hancock and coworkers have described the coordination of Cu(II) with 
protonated ligand, NOTA-H2.33 In this particular case, NOTA-H2 serves as a pentadentate 
ligand where three nitrogens and one acetate arm are coordinated to the metal in a similar 
way as described by Wieghardt. The other two pendant acetate arms are protonated in 
which one is weakly interacting with the metal center and the other is not coordinated at 
all. The coordination sphere is defined by N3O2CI and a twist angle of 33°, giving an 
intermediate geometry between octahedral and trigonal prismatic. This structure, [CuCl-
NOTA-H2] (Figure 1.11), presents a higher level of distortion with respect to the bond 
lengths of the coordination sphere in comparison to [Cu-NOTA]". The reported bond 
lengths for [CuCl-NOTA-H2] has Cu-N bond lengths of 2.07, 2.04, and 2.38 A; one 
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regular and one weak Cu-O bonds of 1.96, and 2.56 A respectively and a Cu-Cl bond 
length of 2.30 A filling the sixth coordination site. In the structure described by 
Wieghardt, [Cu-NOTA]", the Cu-N bond lengths are 2.04, 2.12, and 2.20 A and the Cu-0 
bond lengths are 1.98, 2.14, and 2.21 A. Therefore it is noted that in [Cu-NOTA]", the 
metal is interacting with all donor groups of the ligand, while in [Cu-NOTA-ty, 
protonation of the ligand resulted in a pentadentate chelator with one weak metal-donor 
(05-Cul) interaction. For both structures a type II orientation is observed. 
Peptide conjugation of NOTA converts one acetate arm to an amide by reaction 
with an N-terminal peptide. To gain insight into the high in vivo stability of the reported 
64Cu-NOTA conjugate, a monoamide dicarboxylate analogue of NOTA (NOAM2A) was 
proposed as a target for this research. While the synthesis and full characterization of the 
copper complex of the mono-amide version of Cu(II)-CB-TE2A, Cu(II)-CB-TEAMA, 
have been previously accomplished by the Weisman-Wong lab54, there is no report of 
any NOTA derivative with one amide and two acetate arms. 
1.4 Research Goal 
The aim of this thesis research was the synthesis and characterization of the N-
functionalized TACN, NOAM2A, as a model of the NOTA-peptide conjugate. Its 
coordination chemistry with copper(II), electrochemistry and acid inertness have been 
studied to gauge its resistance to demetallation. We have synthesized NOAM2A in six-
steps from TACN (Scheme 1.3). In addition, we have attempted to prepare Cu(II) 
complexes of these intermediates and to characterize them as well. 
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S c h e m e 1.3: Synthet i c p l a n f o r 4, 5, 6, 7 a n d 8 
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CHAPTER II 
SYNTHESIS OF A^-FUNCTIONALIZED 1, 4, 7-TRIAZACYCLONONANES 
2.1 Introduction 
The chelator NOTA has been shown to possess superior in vivo properties for 
PET overcoming common limitations observed with prior 
BFCs. To gain insight into 
this improved bio-stability, studies of simple models of these bioconjugates are proposed. 
Our interest in synthesizing an iV-fuctionalized-triazacyclononane with an amide in 
addition to the two acetate pedant arms is to prepare such a simple model of the 
conjugated BFC used by Hoffman et al.52'53 O 
HO 









\ / NH' 
ONa 
A NOTA-derived bioconjugate Disodium salt of our bioconjugate model (8) 
Figure 2.01: The NOTA BFC and its simplest model, NOAM2A (8) 
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In order to prepare our pendant-armed target ligand, the need for an efficient and 
selective method for the preparation of its //-protected precursor is necessary. The use of 
a short and efficient synthesis developed by Weisman and coworkers was followed.55"57 
TACN was first prepared as reported.6'9'12'58'59 The synthetic scheme for the preparation 
of 1-formyl-1,4,7-triazacyclononane (4) is shown in Scheme 2.1. Monoprotection of 1 
was accomplished by the introduction of a single iV-formyl group into the parent 9-
membered ring 1. TACN was treated with one equivalent of TV,vV-dimethylform amide 
dimethylacetal (85 °C, 3 h) forming the tricyclic orthoamide (3), followed by the 
hydrolytic reaction of the orthoamide functional group with aqueous hydrochloric acid at 
room temperature to give 4. Purification and characterization of known compounds 3 and 
4 were performed as previously described and corroborated with the reported literature 
data.55"58'60'61 
<N N> . t T l l.aqHCI/rt NS 
V - N - / 85°C \ I / 2. Base work up V - | ] J - y 
A 90% W N ^ 81% ^ H H O 
Scheme 2.1: Synthesis of l-formyl-l,4,7-triazacyclononane (4)53 
2.2 Ligand Synthesis and Characterization 
2.2.1 The synthesis of l-formyl-l,4,7-triazacyclononane-4,7-diacetate diethyl ester(5) 
Precursors l-formyl-l,4,7-triazacyclononane-4,7-diacetic acid diethyl ester (5)62 
and l,4,7-triazacyclonane-4,7-diacetic acid diethyl ester (6)63 have been previously 
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reported. Spiccia et al. also utilized 3 as the starting material but a different approach for 
the introduction of the pendant arms and the formation of 5. Their approach (Scheme 2.2) 
carried out alkylations in two separate steps. The first arm was added by the reaction of 3 
with ethyl bromoacetate to form the quaternary ammonium bromide salt (9), which was 
hydrolyzed to yield the formyl-monoester derivative (10). The second carboxylate ester 
ft 9 group was then attached in a similar fashion as before, but in presence of a base. 
+ CHaCN , N ^ ^ n S ^ 0 ^ ^ -
C D o U J ° 9 • 
3 
9 3 % 
H20 
O \ / O V n V 10 V - N - y Na2C03lCH3CN f 
A 5 8 9 % H ^ O H O 
Scheme 2.2: Reaction scheme used by Spiccia et al. for the synthesis of 562 
In our approach, the two 7V-alkylations were achieved in the same step 
(Scheme 2.3), starting with the jV-formyl monoprotected TACN 4. The two pendant 
carboxylate esters were attached similar to the second alkylation by Spiccia et al. to give 
5 as a clear yellowish oil in 80-90% yields. Characterization data including 'H-NMR and 
^C^HJ-NMR were obtained and corroborated with the reported data.62 Additional data 
such as mass spectrometry and IR spectroscopy were also obtained. 
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4 5 6 
Scheme 2.3: Dialkylation of 4 and formyl bond cleavage of 5 
The attenuated total reflectance infrared (ATR-IR) spectrum of compound 5 
(Figure 2.02) shows typical CH2 bands at 2979, 2909, and 2848 cm"1. The carbonyl 
stretches are observed at 1735 and 1664 cm"1, corresponding to the carboxylate ester 
groups and the formyl group respectively. The electrospray ionization time-of-flight 
(ESI-TOF) mass spectrum (Figure 2.03) exhibits a major peak at 352.1823 m/z which is 
consistent with the [5]Na+ cation with the formula (Ci5H27N3Na05)+. A second peak at 
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Figure 2.02: ATR-IR spectrum of compound 5 
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Figure: 2.03: ESI-TOF mass spectrum of compound 5 
2.2.2 Synthesis of l,4,7-triazacyclonane-4,7-diacetate diethyl ester • 2HC1 (6) 
Compound 6 has been previously reported by Sherry et al.63 One drawback, 
however, is that the described synthetic pathway yielded a mixture of di- and 
tri-substituted intermediates that required relatively long, tedious purification techniques. 
Sherry et al. obtained 6 by a three-step synthesis from TACN«3HC1. In this approach, the 
hydrochloric salt of TACN is dissolved in water at pH 9.5 with 2.1 equivalents of 
bromoacetic acid (Scheme 2.4). It was reported that the reaction gave a mixture of 
products with the primary product being TACN diacetate. This mixture was then purified 
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by ion-exchange chromatography using aqueous hydrochloric acid as the eluent to give 
the pure TACN diacetate tri-hydrochloric salt. This product is then added to a premade 
cold solution of thionyl chloride and ethanol, stirred and warmed to 40 °C. Finally, base 
work up of this reaction mixture gives free amine, 6.63 
Hs / \ M HOs./x I \ ^ s / O H Y > Hn / \ /X^OH N N Q _ T .N N Y O < > 0 N N T 
V N j 3 H C I Aq. NaOH ° ^ J O + • ^ ^ O 
I 40°C | k ^ O | 
H H T H OH 
90% 
1*3HC1 11-3HC1 2 
I \ ^X^OH EtO. I \ 
J / N N ) J 1) SOCI2,2) EtOH ¥ / N Nx J 
V - N ~ ~ / 3 ) 4 0 ° C 0 V - N - - / 
H 8 2 % i 
11 6 
Scheme 2.4: Reported synthesis of free amine 663 
In our approach, the access to 6 is attained by cleavage of the formyl group in 
compound 5. This was accomplished by the reaction of 5 with a dry ethanolic solution of 
hydrogen chloride (Scheme 2.3). Base work up and organic solvent extraction to obtain 
the free amine gave 6 as a yellow oil in very low yields. This was likely because partial 
hydrolysis of the ethyl ester groups had taken place in the work up and most of the 
product remained in the aqueous solution in the hydrolyzed form. Consequently, base 
work up was omitted and the hydrochloride salt of 6 (Scheme 2.3) was purified in a 71% 
yield and used for the next alkylation step. The number of HC1 equivalents per molecule 
of 6 was determined to be two by elemental analysis. The same experimental sample was 
used for other characterizations, i.e. IR and NMR spectroscopy. 
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The structure of 6»2HC1 was confirmed by 'H and ^Cl 'H} NMR spectra 
(Figure 2.04) and (Figure 2.05) and these agree with the assignment of time-averaged 
C2v symmetry. The proton spectrum features a triplet at 5 1.28 and a quartet at 5 4.27 
which are consistent with the ethyl ester groups, a singlet at 5 3.29, and a multiplet at 8 
3.42-3.54 corresponding to the ring protons, and finally a singlet at 5 3.96 assignable to 
the methylene protons of the pendant arms. 
4.8 4.6 4 .4 4 .2 4 .0 3.B 3 .6 3 .4 3 .2 3 .0 2.8 2 .6 2 .4 2 .2 2 .0 1.8 1.6 1.4 1.2 
f l (ppm) 
The ^ C ^ H } NMR spectrum is in agreement with the reported spectrum63 with 
seven carbon resonances in support of an averaged C2v symmetry of the molecule. The 
IR (neat) spectrum (Figure 2.06) of compound 6*2HC1 contains bands in the 2800-3000 
pendant arms as well. The broad N-H bands observed in the 2300 and 2600 cm"1 region 
may be attributed to H-bonding within the molecule. The C=0 stretch of the carboxylic 
ester group is observed at 1738 cm"1. 
Figure 2.04: 'H NMR spectrum (D20,400 MHz) of 6-2HC1, 
residual EtOH set to 5 1.17 
cm"1 region which correspond to the aliphatic C-H stretches from the ring and from the 
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Figure 2.05: ^C^H} NMR spectrum (D20,100.51 MHz) of 6«2HC1 
Figure 2.06: ATR-IR spectrum of compound 6*2HC1 
2.2.3 Syntheses of l,4,7-triazacyclononane-acetamide-4,7-diacetic acid diethyl 
ester(7) 
Using standard alkylation conditions, compound 6 was treated with 
one equivalent of 2-bromoacetamide and excess potassium carbonate in acetonitrile at 
50°C. After a reaction time of one day, the crude material was isolated as a yellow oil 
(Scheme 2.5). Analysis of this crude material by 'H-NMR spectroscopy confirmed the 
presence of the desired product along with impurity peaks. Base work up of this crude 
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material afforded compound 7 sufficiently pure to proceed to the next step. Purity assay 
was based on the NMR and ' ^ { ' H I N M R spectra of the product, Figure 2.07 and 
Figure 2.08 respectively. 
Scheme 2.5: Synthesis of the monoamide diacetate derivative of NOTA, 
NOAM2A (8) 
The structure of compound 7 presents an averaged C2V symmetry as confirmed by 
and ^Cl 'HJNMR spectroscopy. As expected, the proton spectrum shows a splitting 
pattern similar to its precursor with additional singlets at 3.27, 5.43 and 9.29 ppm 
consistent with the new methylene and amide protons. The triplet and quartet of the 
methyl and methylene protons of the ethyl ester arms are displayed at 1.27 and 4.15 ppm 
respectively and finally, the other resonances for the ethylene protons within the ring are 
shown at the 2.80-2.90 ppm region. The "C^HJNMR spectrum reveals 9 different 
carbon resonances in agreement with the C2 symmetry of compound 7. 
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Figure 2.07: 'H NMR spectrum (CDCI3, 400 MHz ) of compound 7 
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Figure 2.08: "C^H} NMR spectrum (CDC13,100.51 MHz) of compound 7 
The IR spectrum (neat) (Figure 2.09) of compound 7 shows aliphatic CH 
stretches at 2841 and 2930 cm"1. The strong bands at 1671 and 1734 cm"1 correspond to 
the two carbonyl stretches of the amide and ester groups respectively. There is a broad 
band in the 3100-3500 cm"1 region which is assignable to the presence of water obscuring 
any NH bands. Proton NMR spectrum also confirms the presence of water by a small 
singlet at 6 1.56. 
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Figure 2.09: ATR-IR spectrum of 7 
The ESI-TOF mass spectrum of 7 (Figure 2.10) exhibits a major peak at 
359.2283 which is consistent with compound 7 agreement with the cation [7]H+ with a 
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Figure 2.10: ESI-TOF spectrum of 7 
2.2.4 Synthesis of disodium l,4,7-triazacyclononane-acetamide-4,7-diacetate (8) 
As previously observed in compound 6, hydrolysis of the ester groups can be 
carried out under mildly conditions. Initially, attempts to dissolved compound 7 in D 2 0 
gave emulsion mixtures, which contained unhydrolyzed and hydrolyzed compound 7 as 
proved by proton NMR. D 2 0 is, in this case, just enough to partially hydrolyzed this 
molecule, but not strong enough to completely hydrolyze it. Figure 2.11 shows the proton 
NMR of 7 after two days in D20. It is most likely that solvent was slightly acidic, which 
allowed for an acid-catalysed ester hydrolysis and an acid catalysed ester formation 
equilibrium. Given that the hydrolysis of esters in acidic media leads to the equilibrium 
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between unhydrolyzed and hydrolyzed species, basic conditions were preferred for this 
step. 
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Figure 2.11: XH NMR (D20, 400 MHz) of 7 after two hours in D 2 0 at room 
temperature, C//3CN set to 2.06 ppm 
Ester groups of compound 7 were hydrolyzed using 1M NaOD at room 
temperature and monitored by *H NMR spectroscopy. Figure 2.12 shows the proton 
NMR spectrum after complete ester hydrolysis, which is supported by the appearance of 
resonances at 1.17 and 3.64 ppm corresponding to the protons of the ethanol formed. 
Nevertheless, this shows irreproducible NMR results and therefore, no definitive NMR 
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Figure 2.12: 'H NMR spectrum (D20, 400 MHz) of 8, EtOH set to 1.17 ppm 
Three resonances at 5 2.62-2.65, 3.22-3.27, and 3.38 with relative integrations of 
twelve, four, and two respectively coincide with the expected number of protons in 
compound 8. However, this is not always the case. For example, differences in the 
splitting pattern and their relative integrations have been observed in other samples. The 
^Cl 'H} NMR spectrum (Figure 2.13) of the hydrolyzed product exhibits only seven 
carbon resonances; two of which are assigned to ethanol carbons "from the hydrolysis and 
only five belong to compound 8. For other samples, six or seven resonances assignable to 
the compound were observed. 
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Figure 2.13: "C^H} NMR spectrum (D20,100.51 MHz) of 8, 
EtOH set to 17.47 ppm 
After complete hydrolysis of compound 7, the solvent was evaporated and the 
residue was re-dissolved in D20, its 'H and 13C{!H} NMR spectra confirm the expected 
disappearance of the ethanol and shows resonances assigned to compound 8 (Figure 
2.14). 
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Figure 2.14: *H NMR spectrum (D20,400 MHz) of 8 after EtOH evaporation, 
residual solvent peak set to 4.79 ppm 
The displayed NMR presents three major resonances with relative integrations 
of 12, 3.6 and 1.3. In the ^Cl 'HJNMR spectrum, (Figure 2.15) nine distinct carbon 
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resonances are observed. Unfortunately, no internal reference for the NMR spectra was 
used; therefore chemical shifts are not very accurate. The obtained spectra allow for 
several interpretations about what is possibly happening. These include possible 
protonation at one or two sites of the molecule and therefore a potential hydrogen 
bonding with the carboxylate oxygens as previously seen in NOTA and TACN diacetate 
(ll).1 '64 '65 Partial hydrolysis of the amide group to a carboxylate group can result in a 
mixture of 8 and NOTA trianion. Amide rotation may be slow enough on the NMR scale 
to differentiate both acetates. Also, a likely deuterium exchange at methylene pendant 
arm protons could explain the observed smaller relative integrations. 
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Figure 2.15: 13C{*H} NMR spectrum (DzO, 100.51 MHz) of 8 after EtOH 
evaporation 
In the ATR-IR spectrum (Figure 2.16), three assignable bands are observed at 
3300, 2807, and 1583 cm"1 which correspond to O-H, C-H, and carboxylate stretches 
respectively. 
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Figure 2.16: ATR-IR spectrum of 8 
For additional characterization data, two samples of 8 were sent for ESI-TOF 
mass spectrometry analysis. However, the major species observed were not in accordance 
with compound 8. 
2.2.5 Synthesis of NOTA (2) 
The synthesis of NOTA was performed following a modified approach by Sherry 
from that reported by Wieghardt described in Chapter I.26'66 NOTA was prepared from 
the tri-substituted tert-butyl acetate TACN intermediate and subsequent deprotection of 
the tert-butyl ester groups with trifluoroacetic acid (TFA) gave the TFA salt of NOTA. 
The tri-substituted intermediate is formed by reacting TACN with three equivalents of 
tert-butyl bromoacetate followed by regular base work up to give the tri-tert-butyl acetate 
TACN (12) as an oil. 
34 
O^OC(CH3)3 
Y / \ 
> BrCH2COOC(CH^3 O 
I1 CH3CN, Na2C03 
H 50°C 







Scheme 2.6: Synthesis of NOTA 
2.3 Summary and discussion 
This chapter described an efficient route to incorporate different functional groups 
into the macrocycle TACN. Compound 7 was selectively prepared through a five-step 
route from TACN. This was accomplished by the addition of a protecting group (1-
formyl) onto one ring nitrogen followed by the alkylation of the other two nitrogens with 
two ethyl ester groups to form intermediate 5. Hydrolysis of the 1-formyl protecting 
group of compound 5 led to the formation of intermediate 6. Finally, incorporation of an 
acetamido group into at the available nitrogen gave 7. This compound has been fully 
characterized through *H and 13C{H} NMR, IR, and ESI MS spectroscopy. NMR spectra 
confirm the expected C2v symmetry for the molecule. Presence of water provides a broad 
peak in the 3100-3400 cm"1 region of the neat IR spectrum obscuring the NH bands. 
Characteristic IR bands corresponding to CH2 and carbonyl stretches contributed to the 
characterization of 7. 
The previously-reported intermediates 5 and 6 were prepared and confirmed by 
'H and/or 13C{H} NMR spectroscopy and additional characterization data including IR, 
ESI MS, and elemental analysis. 
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A sodium salt of compound 8 was prepared by combining 7 with aqueous NaOD. 
However, its and !3C{'H} NMR spectra were irreproducible. To account for this 
irreproducibility, it is proposed that additional species are due to hydrogen bonding with 
various protonated ring nitrogens as was observed for other TACN-acetate compounds 2 
and ll.64 '65 
Geraldes and others demonstrated that at high pH (Table 2.01) NOTA exhibits 
two protonated amine groups, and as a consequence hydrogen bond formation is 
possible between two protonated nitrogens and the two adjacent nonprotonated 
carboxylates as illustrated in Scheme 2.7. The protonation sequence is followed by the 
protonation of the carboxylate groups, leaving the third amine nitrogen to be protonated 
last only at very low pH.1,33,64 
2(I=1M KCL) 11(I=O.IMKCI) 
log K? 11.96[11.3] 11.82[12.05] 
log K? 5.66[5.59] 6.70[6.85] 
log K? 3.37[2.88] 2.87[3.3] 
log K? 1.71 1.02[1.6] 
Table 2.01: Protonation constants of NOTA (2) and TACN-diacetate (11), values in 
square brackets were determined from 1H NMR titration 33'64'65 
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C K , 0 0 ^ . 0 0 ^ . 0 O y O H O ^ O H 
X i—\ / ^ o X /—w X i — „ V i n X /—\+ 
N X H + N N - ^ S ^ O + N + N N ^ V ^ U N N ^ V ^ C 
^ 
V V " V V* HV* 
o o o O o 
Scheme 2.7: Suggested protonation sequence of NOTA 
For compound 11, Lazar et al. concluded that when compound 11 is protonated 
stepwise, the first proton is localized on the secondary amino group the majority of the 
time and this is shared with the two carboxylates and the other two nitrogens 
(Scheme 2.8). Lazar et al. also stated that the carboxylate groups have a significant 
contribution in the first protonation step and their relative high protonation ratio indicates 
hydrogen bonding between a carboxylate and the protonated nitrogen atom.65 In 
Scheme 2.8, the illustrated hydrogen bonding is just a possibility, but it was not 
determined whether hydrogen bonds were of intramolecular or intermolecular nature. The 
protonation constants of 11 are shown in Table 2.01.65 
1 ^ x v ^ o Xr~A X / \ X f \ 
<hv > r + < i > r + < H v > r 
V - N O V - N — / O V - N - ~ / - - 0 1+ - 1+ - T + - - ' 
N 
? 6 
1 „ „ 'l" T "l"+ 
H 11 H H H' 
Scheme 2.8: Suggested first protonation site of 11 
Introduction of the second proton changes significantly the hydrogen bonding 
arrangement. As a result the two protons end up evenly shared by the three ring 
nitrogens. This is associated with possible conformational changes that lead to the 
weakening of the hydrogen bonding between the carboxylates and the ring nitrogen 
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protons. Finally, the third and the fourth protons add to the carboxylate groups with an 
increase of proton density on the tertiary amino groups. (Scheme 2.9).65 
0 ^ . 0 O^O O^OH 0 ^ , 0 H 
X / — \ „ \i—\ \ / — \ 
^ N 7 1 — I — TH 
1+ I+ I + I + H H H H 
Scheme 2.9: Suggested second, third and fourth protonation sites of 11 
It is likely that compound 8 can undergo similar protonation steps as the described 
for NOTA. Therefore even at high pH, at least one amine may be protonated leading to 
hydrogen bonding and conformational changes of 8. The major difference in the 
structure of 8 compared to NOTA is the presence of an amide group instead of an 
acetate group, thus it is likely that at low pH the carbonyl oxygen of the amide group 
gets protonated and cause a hydrolysis. This and other hypothesis can be used to provide 
significant support and explanation for the observed variable spectra of the compound. 
However, more experiments are required in order to corroborate or disprove them. 
Although, mass spectrometry did not correlate to possible species of compound 8 
and no definite NMR data have been obtained to prove the formation of pure compound 
8, its copper (II) complex has been isolated and fully characterized. The coordination 
chemistry of 8 and its precursors will be discussed in Chapter III. 
2.4 Future Work 
The structural behavior of compound 8 in solution is not well understood. It is 
therefore necessary to further investigate this to a complete understanding and full 
characterization of this compound. Potentiometric and NMR studies can be use to 
provide the protonation scheme of compound 8 and an explanation to the changeable 
NMR. 
Temperature variable NMR studies may provide additional information regarding 
to the amide rotation, however hydrolysis of amide group would be very likely to take 
place at high temperature and something that it should be considered. 
Further characterization for compound 8 including elemental analysis and mass 
spectrometry remains to be made. 
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CHAPTER III 
COPPER (II) COORDINATION OF iV-FUNCTIONALIZED 1, 4, 7-
TRIAZACYCLONONANES 
3.1 Introduction 
As mentioned in Chapters 1 and 2, radioisotopes of copper have become 
increasingly important in radio-imaging techniques because copper offers a selection of 
several nuclides with a broad range of nuclear properties for both diagnostic and 
therapeutic purposes. In order to prepare radio-copper carriers, it is essencial that ligands 
satisfy copper's coordination chemistry, forming stable complexes that will survive in 
vivo redox reactions and demetallations. 
Normally, copper can exist in three different oxidation states of (3+)d8, (2+)d9, 
and (l+)d10. Copper in the oxidation states I and II is typically found in most biological 
environments. Cu(II) is a borderline acid and favors borderline bases such as nitrogen and 
chloride. In contrast, Cu(I) prefers softer sulfur-based ligands.67However, copper(II) is 
the oxidation state with the most common aqueous chemistry. The most observed 
coordination numbers for copper(II) are 4, 5, and 6 and it can adopt square planar, square 
pyramidal/trigonal bipyramidal, as well as tetragonal geometries. Copper(I) ion is often 
found in a pseudo-tetrahedral geometry, but, its coordination number varies a lot. 
Copper(III) is relatively uncommon and difficult to obtain. Copper complexes in this 
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oxidation state usually adopt a square planar geometry. Since copper (II) is more stable 
and easier to manipulate, it is therefore the oxidation state used in the design of 
radiopharmaceuticals. 
Zinc is a constituent of many enzymes which are present in several metabolic 
processes and is therefore essential for life.67 The predominant and almost invariant 
oxidation state of Zn is 2+ and it is the form found in all living systems. Similar to Cu(II), 
Zn(II) is a borderline acid which forms stable complexes with a variety of donor ligands 
including oxygen, nitrogen, sulfur, and halogen donors. An assortment of high and low 
coordination numbers and various stereochemistries are found in Zn(II) complexes, 
however 4-coordinate tetrahedral geometry seems to be favored biologically.68 
In this chapter the coordination chemistry of Cu(II) and Zn(II) with N-
functionalized pendant arms TACN ligands containing O- and //-donors will be 
described. 
3.2 Synthesis and Characterization of Copper (II) Complexes 
Copper complexes of ligands 4, 5, 6, and 7 were prepared following a general 
procedure. This is illustrated in Scheme 3.1 
N .N N 
EtOH . ( /. . . „ 
N—/ +M( , l )Sa , t T ' V N V ' M 
R' R' 
Scheme 3.1: General protocol for M (II) complexation with ligands 4, 5, 6, and 7 
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M(II) salt Ligand Complex 
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S N H 2 
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Table 3.01: List of ligands and metal complexes 
The general complexation procedure consisted of dissolving the ligand and the 
metal (II) salts in absolute ethanol, followed by their combination and stirring overnight 
at room temperature. 
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3.2.1 Copper and Zinc Complexes of 1-formyl-l, 4, 7-triazacyclonoane (4) 
Our interest in the coordination chemistry of 4 was piqued by the presence of a 
tertiary amide. Metal complexes containing TV-coordinated tertiary amides are rare and 
very few well-characterized examples have been reported to date.69"74 Typically, amide 
groups bind the metal through their carbonyl oxygen given that amides are resonance 





o : *~M 
Scheme 3.2: Derealization of nitrogen's lone pair into a n system leads to 
favorable binding at the more basic carbonyl oxygen 
Copper (II) complex formation with ligand 4 was observed by the appearance of 
an instant precipitate when the ligand and the copper nitrate solutions were combined. 
This precipitate was collected and dried to give 13 as a lilac-blue solid in very good yield. 
Several attempts to obtain X-ray quality crystals for compound 13 were unsuccessful. 
The neat infrared spectrum of 13 (Figure 3.01) shows the characteristic NH and 
C=0 stretches at 3305 cm"1 and 1676 cm"1 respectively. The carbonyl peak of the 
complex has shifted to higher energy with respect to the free ligand value of 1641 cm"1. 
This suggests a possible interaction of the amide nitrogen with the metal center. It is 
known that derealization of the lone pair of the nitrogen of amides leads to the 
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resonance form illustrated in Scheme 3.2. Nitrogen metal coordination would decrease 
that derealization, thus the double bond character between carbon oxygen should 
increase as a result. 
1 76 
Other observed bands at 1469 and 1286 cm" suggest a coordinated nitrate. The 
UV-Vis spectrum of 13 displays an absorption maximum at 661 nm and a molar 
1 1 77 
absorptivity of 46 M" cm" , which is similar to other copper complexes of TACN 1. The 
elemental analyses confirm the formula CUC7H15N5O7 which constitutes a ratio of 2:1:1 
(nitrate: ligand: metal). 
It was interesting to see a solid-state reaction of 13 in the KBr pellet. A color 
change was observed a few hours after making the pellet as the coordinated nitrate peaks 
disappeared from the IR spectrum. Figure 3.02 illustrates theses changes in the IR (KBr) 
spectrum of 13 over time. The bromide ion is likely substituting for the coordinated 
nitrates. This is in accord with literature reports that the nitrate ion is generally 
considered to be a weak ligand.77 By contrast, attenuated total reflectance infrared 
(ATR-IR) spectra of 13 did not change over time. 
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Figure 3.02: Changes in the IR(KBr) spectrum of complex 13 
Compound 14, a Zn(NC>3)2 complex of ligand 4, was obtained in 27% yield. This 
complex is a white solid that seems to decompose readily over time, color changes of 
complex 14 were observed from white to yellowish. Characterization of data of 14 such 
as ATR-IR, NMR, and X-ray crystallography provides good evidence of amide 
nitrogen metal interaction. In the IR the Uco amide stretch of 14 was observed at 1656 
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cm"1, this is shifted slightly towards higher energy from that of the free ligand value of 
1641 cm"1. Coordinated nitrate bands are seen at 1464 and 1290 cm"1. A KBr pellet of 14 
showed a different IR spectrum compared to its neat spectrum since non-coordinated 
nitrates peaks are seen as soon as the KBr pellet was made (Figure 3.03). Presumably, a 
solid state reaction occurred similar to that observed for complex 13. 
Since complex 14 was insoluble in all organic solvents and just slightly soluble in 
water " C ^ H } NMR was not well resolved and only good proton NMR data was 
obtained (Figure 3.04). This spectrum reveals six multiplets at 5 2.90-2.95, 5 3.04-3.09, 5 
3.12-317, 8 3.24-3.29, 8 3.50-3.54, and 8 3.57-3.62 and a singlet at 8 8.14. This is 
important since the time-averaged Cs symmetry indicates that amide rotation is fast on the 
NMR time confirming an amide N-coordination. In addition, single-crystal X-ray 
crystallographic data of a crystalline sample corroborated the amide N-metal interaction 
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and the formation of compound 14 despite 
provide useful characterization data. 








3 5 3.0 
ppm 
Figure 3.04: H NMR spectrum (D20, 500 MHz) of 4 and 14, C//3CN set to 2.06 
The coordination chemistry around the metal center of 14 can be described as a 
distorted octahedral geometry. Its X-ray structure (Figure 3.05), shows two nitrogen 
donors from the medium sized ring strongly coordinated to the metal; three other Zn 
coordination sites are occupied by two nitrate groups, and an ethanol molecule. Most 
interestingly, zinc cation shows an additional interaction with the nitrogen N(4) of the 
tertiary amide at a Zn(l)-N(4) distance of 2.795(1) A completing the sixth coordination 
site. This interaction allows for deviations from planarity of the tertiary amide function, 
thus the nitrogen atom N(4) is no longer truly sp2 hybridized and the sum of the C-N(4)-C 
angles add up to 355°. Important bond lengths and bond angles are summarized in (Table 
3.02). 
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Figure 3.05: X-ray structure of complex 14 
Zn(l)-0(1) 2.073(1) Zn(l)-0(8) 2.066(2) Zn(l)-N(5) 2.123(1) 
Zn(l)-0(4) 2.093(1) Zn(l)-N(3) 2.102(2) Zn(l)-N(4) 2.795(1) 
0(l)-Zn(l)-0(4) 90.12(5) 0(4)-Zn(l)-0(8) 79.21(5) 0(8)-Zn(l)-N(5) 96.03(5) 
0(l)-Zn(l)-0(8) 104.39(5) 0(4)-Zn(l)-N(3) 96.05(5) N(3)-Zn(l)-N(5) 81.53(5) 
0(1)-Zn(l)-N(3) 97.82(5) 0(4)-Zn(l)-N(5) 161.82(5) 
0(1)-Zn(l)-N(5) 108.06(5) 0(8)-Zn(l)-N(3) 157.25(5) 
*esd in parentheses. Refer to the end of section 3.2 for additional crystallographic data. 
Table 3.02: Selected bond lengths (A) and angles (°) for complex 14 
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3.2.3 Copper Complex of Ligand 6 
EtO O EtO 
Y .N N Y 
\—N—/ 
OEt 
The coordination chemistry of compound 5 is also of interest due to the presence 
of a ring tertiary amide as well as ester pendant arms. Complex 15 was formed by the 
procedure described in Scheme 3.1, whereby ethanolic solutions of copper chloride and 
ligand 5 were combined forming a homogenous green solution. After the solvent was 
evaporated, the crude material was dissolved in methanol and precipitated with ethyl 
acetate. X-ray quality blue crystals were grown by layering ethyl acetate onto a MeOH 
solution of the complex. Ligand 5 is in this case hydrolyzed at some point during the 
complexation or recrystallization procedure. Characterization data, such as ATR-IR 
spectroscopy and X-ray crystallography, provided evidence for the formation of complex 
15. Its structure, which is displayed in Figure 3.07, reveals that one of the ester arms of 
ligand 5 has been hydrolyzed. The most likely cause of this hydrolysis is the presence of 
water. It is important to mention that similar ester hydrolysis has also been observed with 
previously described compound 6. 
The IR spectrum of this complex (Figure 3.06) shows four bands at 1734, 1714, 
1669, and 1646 cm"1 characteristic of carbonyl and carboxylate stretches in accordance 
with the ester, acetate, and probably two amide rotamers. The elemental analyses match 
best the molecular formula CuC13H22N305Cl (NaCl) (1.3 CH3CH2OH) which correspond 
to compound 15. The electronic spectrum of 15 in water shows an absorption maximum 
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Figure 3.06: ATR-IR spectrum of 15 
The X-ray structure of 15 is displayed in Figure 3.07 and selected bond lengths 
and angles are listed in Table 3.03. The coordination mode of this complex is categorized 
by five different types of donor atoms illustrating a very distorted arrangement, therefore 
it was difficult to assign a definite geometry. The interactions with the copper center are 
defined by one acetate oxygen, one chloride and two nitrogen atoms from the medium 
sized ring with an average distance of 2.075 A. In addition, an ester carbonyl oxygen 
0(2) and a tertiary amide nitrogen N(3) are weakly interacting with this metal center 
with distances of Cu(l)-0(2) and Cu(l)-N(3) of 2.618(4) A and 2.609(4) A respectively. 
The interaction of the amide nitrogen with the metal center affects the structure around 
this nitrogen causing a small pyramidalization. This distortion is similar to the described 
for the amide nitrogen of compound 14 with the sum of the C-N(3)-C angles also equal to 
355°. Moreover, compound 15 shows a slightly longer bond length of the N(3)-C(formyl) 
with a distance of 1.366 A in comparison to the N(3)-C(formyl) bond of the ligand with a 
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value of 1.335 A. Orientation of pendant arms described a type II mode, forming two 
five-member chelate rings. 
Figure 3.07: X-ray structure of complex 15 
Cu(l)-Cl(l) 2.261(1) Cu(l)-0(2) 2.618(4) Cu(l)-0(3) 1.939(4) 
Cu(l)-N(l) 2.060(4) Cu(l)-N(2) 2.041(4) Cu(l)-N(3) 2.609(4) 
Cl(l)-Cu(l-02 83.5(1) 0(2)-Cu(l)-0(3) 96.8(1) 0(3)-Cu(l)-N(2) 84.2(2) 
Cl(l)-Cu(l)-0(3) 95.5(1) 0(2)-Cu(l)-N(l) 71.8(1) 0(3)-Cu(l)-N(3) 113.9(1) 
Cl(l)-Cu(l)-N(l) 99.6(1) 0(2)-Cu(l)-N(2) 107.7(2) N(l)-Cu(l)-N(2) 83.6(2) 
Cl(l)-Cu(l)-N(2) 168.8(1) 0(2)-Cu(l)-N(3) 149.3(1) N(l)-Cu(l)-N(3) 79.5(1) 
Cl(l)-Cu(l)-N(3) 91.0(1) 0(3)-Cu(l)-N(l) 159.7(2) N(2)-Cu(l)-N(3) 79.0(2) 
*esd in parentheses. Refer to the end of section 3.2 for additional crystallographic data. 
Table 3.03: Selected bond lengths (A) and angles (°) for complex 15 
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3.2.3 Copper Complex of Ligand 6 
T N T 
H 
The coordination chemistry of ligand 6 is of interest for its five potential donor 
sites for coordination with metal ions. Pentadentate ligands of this class are currently of 
interest since they can be used to anchor mononuclear octahedral complexes that have a 
7 8 
single open coordination site for binding and activation of small molecules. 
The synthesis of complex 16 from 6 was carried out similarly as the complexes 
described above (Scheme 3.1). This complex was characterized by elemental analysis, IR 
and UV-vis spectra and X-ray crystallography. The maximum absorption in the visible 
region of the electronic spectrum is observed at 694 nm. Elemental analysis of this 
product confirmed the formula CuCi4H27N304Cl2(0.5H20). 
In its IR spectrum, a sharp and strong band appeared at 1732 cm"1, this is 
consistent with typical ester carbonyl stretches. Thus despite presence of both 
coordinated and uncoordinated esters in the X-ray structure (Figure 3.08), only one 
resolved carbonyl peak was seen. This is likely the result of a weak interaction of the 
0(1)-Cu(l), which has a distance of 2.743 A, and does not really affect the ester carbonyl 
stretches. The bond distances for the C=0 of the uncoordinated and coordinated esters are 
1.205 A and 1.220 A respectively. 
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Figure 3.08: View of the X-ray structure of complex 16 
Blue rhombic plates of X-ray quality were grown by slow cooling of a hot 
solution of 16 in ethanol. The structure of the complex consists of monomeric, neutral 
molecules of Cu-6 (Figure 3.08). The copper ion is coordinated by just four atoms of the 
pentadentate ligand. Three nitrogens occupy one facial position of a distorted octahedron 
and the other face is occupied by an oxygen atom from one pendant arm and two 
chlorides. The Jahn-Teller distortion in this complex is evident by the elongation of one 
of the axial bonds with a very long distance Cu(l)-0(1) of 2.743(2) A and Cu(l)-N(2) 
bond of 2.308(2) A. Compression of the trans angles to less than the ideal angle (180)° 
are observed for Cl(l)-Cu(l)-N(l), Cl(2)-Cu(l)-N(3), N(2)-Cu(l)-0(1) which are 
173.16(7), 174.26(7), 151.83(7) respectively. Other bond distances and bond angles are 
summarized in Table 3.04. 
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Cl(l)-Cu(l) 2.315(1) Cl(2)-Cu(l) 2.300(1) Cu(l)-N(l) 2.115(2) 
Cu(l)-N(2) 2.308(2) Cu(l)-N(3) 2.051(3) Cu(l)-0(1) 2.743(2) 
Cl(l)-Cu(l)-Cl(2) 94.07(3) Cl(2)-Cu(l)-N(l) 91.32(7) N(l)-Cu(l)-N(3) 83.37(9) 
Cl(l)-Cu(l)-N(l) 73.16(7) Cl(2)-Cu( 1 )-N(2) 99.69(6) N(l)-Cu(l)-0(1) 69.95(8) 
Cl(l)-Cu(l)-N(2) 100.86(6) Cl(2)-Cu( 1 )-N(3) 174.26(7) N(2)-Cu(l)-N(3) 81.82(9) 
Cl(l)-Cu(l)-N(3) 91.07(7) Cl(2)-Cu(l)-0(1) 86.29(5) N(2)-Cu(l)-0(1) 151.83(7) 
Cl(l)-Cu(l)-0(1) 106.18(5) N(l)-Cu(l)-N(2) 82.34(9) N(3)-Cu(l)-0(1) 89.82(8) 
*esd in parentheses. Refer to the end of section 3.2 for additional crystallographic data. 
Table 3.04: Selected bond lengths (A) and angles (°) for complex 16 
3.2.4 Copper Complex of Ligand 7 
T .N N T 
V - N - / 
NH2 
Complex 17 was obtained by the reaction of 7 with copper chloride as in 
Scheme 3.1. This complex was characterized spectroscopically and structurally. The 
electronic spectra of 17 in aqueous solution shows a maximum at 716 nm with a molar 
absorptivity 8 = 57 M^cm"1. Its solid state IR spectrum displays three carbonyl stretches 
assignable to both uncoordinated and coordinated esters at 1738 and 1723 cm"1 
respectively and one amide carbonyl at 1660 cm"1. Its elemental analysis corresponds to 
the empirical formula CUC16H30N4O5CI2 (0.3NaCl)(0.7H20). 
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Figure 3.09: X-ray structure of complex 17 
The X-ray structure of 17 consists of the complex cation [CuCl-7]+ (Figure 3.09), 
an uncomplexed triiodide ion, and a molecule of ethanol. Triiodide ion is not a reagent in 
the complexation reaction; however potassium iodide is part of the reagents in the ligand 
synthesis. Therefore, the most likely reason for the presence of triiodide ion is that traces 
of KI were present in the ligand solution used. Iodide can be easily air oxidized to I2 to 
give I3. Compound 17 was prepared using the crude material of the ligand synthesis 
shown in Scheme 3.3. Note that synthesis of compound 7 was reported in Chapter 2 and 
it is slightly different than the synthesis in Scheme 3.3. 
6 7 
Scheme 3.3: Synthesis compound 7 
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Ligand 7 contains six potential donor atoms for complexation with metals ions, 
however only five are coordinated to the copper center in complex 17. Its coordination is 
defined by the N3O2CI sphere, where three nitrogens occupy one face of a distorted 
octahedron while the other face is occupied by two ester carbonyl oxygens, and a 
chloride. The Jahn-Teller elongated Cu(l)-0(2) bond length of 2.566(6) A and Cu(l)-
N(3) distance of 2.265(7)A as well as non-ideal Cl(l)-Cu(l)-N(l), N(3)-Cu(l)-0(2), 
N(2)-Cu(l)-0(1) trans angles of 173.8(2), 155.5(2), 166.9(2)° respectively are observed. 
Additional structural data for the complex are listed in Table 3.05. 
Cl(l)-Cu(l) 2.258(1) Cu(l)-N(l) 2.043(5) Cu(l)-N(2) 2.072(5) 
Cu(l)-N(3) 2.265(7) Cu(l)-0(1) 2.004(4) Cu(l)-0(2) 2.566(6) 
Cl(l)-Cu(l)-N(l) 73.8(2) N(l)-Cu(l)-N(2) 85.1(2) N(2)-Cu(l)-0(1) 166.9(2) 
Cl(l)-Cu(l)-N(2) 98.9(2) N(l)-Cu(l)-N(3) 83.9(2) N(2)-Cu(l)-0(2) 72.4(2) 
Cl(l)-Cu(l)-N(3) 101.2(1) N(l)-Cu(l)-0(1) 82.4(2) N(3)-Cu(l)-0(1) 99.0(2) 
Cl(l)-Cu(l)-0(1) 93.3(1) N(l)-Cu(l)-0(2) 90.7(2) N(3)-Cu(l)-0(2) 155.5(2) 
Cl(l)-Cu(l)-0(2) 86.1(1) N(2)-Cu(l)-N(3) 83.3(2) 0(l)-Cu(l)-0(2) 104.0(2) 
*esd in parentheses. Refer to the end of section 3.2 for additional crystallographic data. 
Table 3.05: Selected bond lengths (A) and angles (°) for complex 17 
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3.2.5 Copper Complex of Ligand 8 
N / N N. N 
° V - - N - V ° 
k ^ O 
NH2 
The synthesis of compound 18 is shown in Scheme 3.4. An aqueous solution of 
ligand 8 at pH 7 was combined with an aqueous solution of CuCl2*2H20 and the reaction 
mixture readjusted to pH 7. This homogeneous solution was stirred at room temperature 
overnight under nitrogen atmosphere. At this point, water was evaporated and the 
residual blue crystalline film was dissolved in absolute ethanol. An insoluble light-blue 
material was removed by centrifugation and the supernatant was evaporated to dryness to 
give blue crystals. The final product was recrystallized by slow cooling from ethanol and 
water to give cubic crystals suitable for X-ray analysis. 
Y > N> J >Vn^Y0 
° V n V ° r . , r , _ .ou_n HyO, pH=7, ( - N " ^ + CUCI2-2H20 • • •^ •K" '» 
N H * NH2 
8 18 
Scheme 3.4: Cu(II) complexation with ligand 8 
In the IR spectrum of complex 18 the N-H and carbonyl stretches are displayed. 
The N-H stretches are shown at 3450 and 3305 cm"1. The amide C=0 stretch is observed 
at 1652 cm"1, which is at a lower wavenumber than value observed for the free ligand, 
1678 cm"1, and it is consistent with carbonyl oxygen coordination. For the carboxylate 
carbonyl stretches the free ligand is 1583 cm"1 while for the complex is 1605 cm"1. Its 
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maximum absorption in aqueous solution is observed at 719 nm with a molar absorptivity 
of • = 68 M"1 cm"1. 
The X-ray crystal structure of Cu-8 shows an intermediate geometry between 
distorted octahedral and trigonal prismatic given by a twist angle of 33° (Figure 3.10) as 
compare to 27° for Cu-NOTA. Copper (II) is enveloped by all three nitrogens and three 
oxygens of the ligand with the acetate groups oriented counterclockwise in a type II 
conformation. This coordination mode is similar to that of Cu-NOTA reported by 
Wieghardt.26 
Figure 3.10: X-ray structure for complex 18 
Cu-NOTA presents Cu-N bond lengths of 2.04, 2.12, and 2.20 A as compared to 
2.00, 2.12, and 2.20 A for Cu-8. The Cu-0 bond lengths are 1.98, 2.14, and 2.21 A as 
compared to 1.97, 2.05, and 2.28 A for Cu-8. 
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Cu(l)-0(1) 1.973(1) Cu(l)-0(3) 2.045(1) Cu(l)-0(5) 2.284(1) 
Cu(l)-N(l) 2.122(2) Cu(l)-N(2) 2.001(2) Cu(l)-N(3) 2.200(2) 
0(l)-Cu(l)-0(3) 93.88(6) 0(3)-Cu(l)-0(5) 91.64(5) 0(5)-Cu(l)-N(2) 107.15(6) 
0(l)-Cu(l)-0(5) 88.82(5) 0(3)-Cu(l)-N(l) 117.00(6) 0(5)-Cu(l)-N(3) 73.90(6) 
0(1)-Cu(l)-N(l) 81.56(6) 0(3)-Cu(l)-N(2) 82.32(6) N(l)-Cu(l)-N(2) 85.98(7) 
0(1)-Cu(l)-N(2) 163.62(6) 0(3)-Cu(l)-N(3) 155.51(6) N(l)-Cu(l)-N(3) 81.50(6) 
0(1)-Cu(l)-N(3) 105.22(6) 0(5)-Cu(l)-N(l) 150.19(6) N(2)-Cu(l)-N(3) 83.26(6) 
*esd in parentheses. Refer to the end of this section for additional crystallographic data. 
Table 3.06: Selected bond lengths (A) and angles (°) for complex 18 
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Identification code Complex 14 Complex 15 Complex 16 
Empirical formula Cio H25 N5 Og 50 Zn CI5 H25 CI Cu N4 05 C18 H34 C12CUN304 
Formula weight 416.72 440.38 490.92 
Temperature 123(2) K 100(2) K 150(2) K 
Wavelength 0.71073 A 0.71073 A 0.71073 A 
Crystal system Triclinic Monoclinic Monoclinic 
Space group P-l P2(l)/n P2(l)/c 
Unit cell dimensions 
a (A) 7.8884(5) 7.0767(9) 12.289(7) 
B(A) 9.8961(6) 17.242(2) 14.298(8) 
c(A) 11.4324(7) 15.315(2) 12.931(7) 
68.1680(10) 90 90 
89.3730(10) 94.817(2) 102.835(7) 
Y(°) 89.1390(10) 90 90 
Volume (A3) 828.35(9) 1862.1(4) 2215(2) 
Z 2 4 4 
Density (calculated) 1.671 g/cm3 1.571 Mg/m3 1.472 Mg/m3 
1.255 mm"1 Absorption coefficient 1.537 mm-1 1.350 mm"1 
F(000) 436 916 1032 
Crystal size (mm3) 0.30 x 0.27 x 0.24 0.20x0.15x0.12 0.29x0.16x0.08 
Crystal color, habit blue / block Blue-Green Plate 
Theta range for data 1.92 to 25.75° 1.78 to 26.53° 1.70 to 27.48° 
collection 
Index ranges -9<=h<=9, -8<=h<=8, -15<=h<=15, 
-12<=k<=12, 0<=k<=21, -17<=k<=18, 
Reflections collected -13<=1<=13 0<=1<=19 -16<=1<=15 
Independent reflections 9500 22,417 20498 
Completeness to theta = 3162 [R(int) = 0.0181] 3849 [R(int) = 0.0510] 4913 [R(int) = 0.0535] 
25.00° 99.8 % 99.6 % 99.8 % 
Absorption correction 
Max. and min. None multi-scan/ sadabs Multi-scan 
transmission 0.7093 and 0.6557 0.8547 and 0.7739 0.9030 and 0.7153 
Refinement method Full-matrix least- Full-matrix least- Full-matrix least-
squares on F2 squares on F2 squares on F2 
Data / restraints / 3162 /0 /235 3849 /0 /236 4913 /0 /249 
parameter 
Goodness-of-fit on F2 1.111 1.065 1.040 
Final R indices R1 = 0.0215, wR2 = R1 = 0.0625, wR2 = R1 = 0.0430, wR2 = 
[I>2sigma(I)] 0.0564 0.1783 0.0959 
R indices (all data) R1 = 0.0224, wR2 = R1 = 0.0721, wR2 = R1 =0.0641, wR2 = 
0.0569 0.1842 0.1057 
Largest diff. peak and 0.374 and-0.588 e A"3 1.184 and-0.832 e.A"3 0.630 and-0.515 e.A"3 
hole 
Table 3.07: Crystal data for compounds 14,15, and 16 
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Identification code Complex 17 Complex 18 
Empirical formula CIG H 3 6 C I C u I 3 N 4 O 6 C,2 H26 CUN408 
Formula weight 884.20 417.91 
Temperature 150(2) K 173(2) K 
Wavelength 0.71073 A 0.71073 A 
Crystal system Triclinic Monoclinic 
Space group P-l P2(l)/n 
Unit cell dimensions 
a (A) 14.7261(10) 9.0561(7) 
b(A) 5.0430(10) 12.9139(11) 
c(A) 15.3459(11) 14.4933(11) 
an 77.1670(10) 90 
61.8290(10) 93.0990(10) 
r ( ° ) 84.4100(10) 90 
Volume (A3) 2921.8(3) 1692.5(2) 
z 4 4 
Density (calculated) 2.010 Mg/m3 1.640 g/cm3 
Absorption coefficient 4.046 mm"1 1.341 mm"1 
F(000) 1700 876 
Crystal size (mm3) 0.37x0.35 x0.24 0.24x0.22x0.10 
Crystal color, habit Red Block Pale blue plate 
Theta range for data 1.85 to 28.29° 2.11 to 25.69° 
collection 
Index ranges -19<=h<=19, - l l<=h<=ll , 
-19<=k<=20, -15<=k<=15, 
-20<=1<=19 -17<=1<=11 
Reflections collected 33196 16761 
Independent reflections 12875 [R(int) = 0.0254] 3169 [R(int) = 0.0387] 
Completeness to theta = 97.9 % 98.8 % 
25.00 
Absorption correction Multi-scan Multi-scan 
Max. and min. 0.4435 and 0.3160 
transmission 
Refinement method Full-matrix least- Full-matrix least-squares 
squares on F2 onF2 
Data / restraints / 12875/0 /603 3 1 6 9 / 9 / 2 4 4 
parameter 
Goodness-of-fit on F2 1.047 1.055 
Final R indices R1 = 0.0565, wR2 = R1 = 0.0271, wR2 = 
[I>2sigma(I)] 0.1526 0.0616 
R indices (all data) R1 = 0.0633, wR2 = R1 =0.0321, wR2 = 
0.1579 0.0650 
Largest diff. peak and 4.669 and-4.138 e.A"3 0.391 and-0.416 e A"3 
hole 
Table 3.08: Crystal data for compounds 17 and 18 
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3.3 Electrochemistry and Acid Inertness of Cu(II) Complexes 
Dissociation of copper from bioconjugate complexes in vivo compromises their 
efficacy for PET. This has been observed with 64Cu BFCs of TETA and DOTA, but 
higher resistance to such dissociation has been observed with the BFC of NOTA. 
Possible in vivo reduction of Cu(II) in its chelate complexes can play a detrimental role in 
that the less stable Cu(I) complex can dissociate and bind to a variety of biomolecules. 
Other feasible in vivo dissociations of the 64Cu(II) from the bioconjugate can take place 
by reaction of the BFC with protons or biological metal ions. We have therefore 
examined the cyclic voltammetry as well as the acid inertness of these new model 
complexes. These experiments were performed by Dr. Edward Wong. 
3.3.1 Cyclic voltammetry 
Cyclic voltammetry experiments were carried out in 0.1 N aqueous sodium 
acetate solutions at room temperature. Table 3.09 shows the reduction potentials for 
relevant copper complexes. 
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[ C U - W R - 0 . 5 V , - 1 . 3 V 
Irreversible 
[CU-(1)2]Z+ - 0 . 5 V , - 1 . 3 V 
Irreversible 
[Cu-4f+or(13) - 0 . 3 V 
Irreversible 
[CU-5]2+ or (15-15') - 0 . 0 7 V 
Irreversible 
[Cu-6]2+ or (16) - 0 . 5 V 
Irreversible 
[Cu-7]z+ or (17) - 0 . 7 V 
Irreversible 
[Cu-NOTA]" or [Cu-2]" - 0 . 9 V , - 1 . 2 V 
Irreversible 
[Cu-NOAM2A] or (18) - 0 . 8 V 
Irreversible 
Cu-CB-TE2A - 1 . 0 3 V 
Quasi-reversible79 
Table 3.09: Electrochemical studies of copper (II) complexes 
All copper complexes studied here yielded irreversible reductions. None of the 
ligands seem to be able to adapt to the coordination of Cu(I) and stabilize it. It is most 
likely that for all complexes, Cu(I) readily dissociated from the ligand after reduction and 
then the free Cu(I) disproportionated to yield Cu(0) and Cu(II) (Scheme 3.5). Large 
stripping peaks indicative of Cu(0) are present in all voltammograms upon return 
scanning. 
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Reduction Cu(l)L Cu(ll)L + e \ Fast Cu(l) dissociation 
1/2eqCu(ll) + 1/2eqCu(0) Cu(l) + L 
Cu(l) disproportionation 
Oxidation stripping peak - e 
1/2eqCu(ll) 
Scheme 3.5: Potential species formed during electrochemistry studies 
3.3.2 Acid-Assisted Decomplexation Studies 
Aqueous acid dissociation studies of copper complexes can be used to predict 
whether or not the complexes will survive in vivo. Such half-lives are frequently used as 
first indicators of how long a compound will persist under harsh conditions. Copper 
complexes in 1M acid at various temperatures and their half-lives were therefore 
determined spectroscopically. In these studies, decomplexation was quantitatively 
monitored using UV-vis spectroscopy. The d-d transitions for these copper complexes 
occur in the range between 600 and 750nm. The slope of the ln(absorbance) vs. time of 
the Xmax peak from the kinetic data gives the pseudo first order half-life of the complex. 
These results are summarized in Table 3.10. 
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Complex Half life in 
1MHC1 
30°C 
Half life in 
1MHC1 
90°C 
Half life in 
5M HC1 
30°C 
[Cu-(1)C12] < lmin 
[Cu-(1)2]C12 < lmin 
[Cu-2]" Months 23(4) days < lmin 
18 Months 32(1) days < lmin 
Cu-CB-TE2A >350 days 
Table 3.10: Acid decomplexation studies of copper(II) complexes 
Even though Cu-TACN, Cu-(TACN)2 and Cu-NOTA are well-known complexes, 
their half-lives in acidic media have not been determined. These complexes were 
synthesized, and their stabilities in acidic solutions were determined. 
At room temperature both Cu-TACN and Cu-(TACN) decomplexated 
immediately after dissolution in 1M HC1 solution as opposed to Cu-NOTA which did not 
change over a month. Another solution of this complex was then tested at 90°C with the 
same acid concentration. In this case a half life of 23(4) days was determined. Lastly, Cu-
NOTA was dissolved with 5M aqueous HC1 yielding an instantaneous decomplexation. 
The same procedure was followed to determine the half life of the model copper 
bioconjugate analogue, Cu-NOAM2A. Like Cu-NOTA, this complex showed no change 
in 1M HC1 at room temperature and instant dissociation in 5M acid. Its half life was 
determined to be 32 days when kept in 1M aqueous HC1 at 90°C. 
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3.4 Summary and Conclusions 
Zn(II) and Cu(II) complexes of ligand 4 were obtained and folly characterized. 
The X-ray structure of the Zn complex verified an N-amide interaction with metal center 
with a distance of 2.8A. There was not an X-ray structure for Cu-4 to confirm such an 
interaction, but an IR band at 1676 cm"1 for the carbonyl of Cu-4 is higher in energy that 
of the ligand at 1641 cm"1, supporting a similar rare amide N-Cu coordination. 
Disappearance of nitrate peaks in the IR spectrum when a KBr pellet was used for 
analysis of both of these complexes led us to conclude that a solid state reaction occurred. 
Presumably, the Br" ions displaced the coordinated nitrates. 
Cu(II) complexes with ligands 5, 6, 7, and 8 have been prepared. These 
complexes have been fully characterized and X-ray structures have been obtained. 
Typical distorted octahedral geometry is observed in all structures. These complexes 
presented a UV-vis A^x from 600 to 750nm with molar absorptivities of less than 100 M" 
^m"1 which are typical for d-d transitions of pseudo-octahedral Cu(II) complexes. 
Even though electrochemistry studies showed irreversible reductions for all 
copper complexes, the reduction peak potentials of -0.9V and -0.8V for Cu-NOTA and 
Cu-NOAM2A are most likely negative enough to resist biological reduction. 
The kinetic inertness studies confirmed that both Cu-NOTA and Cu-NOAM2A 
are significantly more stable kinetically than the copper complex of the unsubstituted 
TACN. While neither approach the extreme inertness of the Cu-CBTE2A, they appear 
sufficiently robust for typical in vivo pH's. 
In conclusion, our coordination chemistry, acid inertness, and electrochemistry 
studies suggest that coordination of the pendant arms in the chelating ligand NOTA and 
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its derivatives likely to contribute significantly to the in vivo stability of the radio-labeled 
bioconjugates. 
3.5 Future Work 
The copper complex of compound 8 was made as a model of the 64Cu-NOTA-
bioconjugate, however the use of a TACN-diacetate derivative containing a secondary 
amide instead of a primary amide can be a better model of this bioconjugate. 
Although, 2-chloro-7V-phenylactetamide was initially used to synthesize a 
monoamide TACN-diacetate diethyl ester derivative, further exploration of this 
compound remains to be made. The hydrolysis of the ester groups can be performed in 
basic solution and concerns about the hydrolysis of amide group may be diminished for 
the presence of a secondary amide. Complexation with copper (II) can be performed 
similar to how compound 18 was prepared. 
NMR studies of a zinc complex of compound 8 may be useful to explore the 
behavior of this ligand in aqueous solution when complexed to metal centers. Other 




4.1 General Methods and Materials 
Elemental Analysis (CHN) was performed by Atlantic Micro-Labs Inc., Atlanta 
Georgia, USA. High Resolution Mass Spectra Electrospray Ionization Time-of-Flight 
(HR-MS-ESI-TOF) for compounds (5, 7) were obatined at the University of Notre Dame. 
Infrared Spectra (IR) were run on a Nicolet iSlO FT-IR spectrometer (attenuated total 
reflectance). NMR Spectra (*H NMR and 13C{]H} NMR) were acquired on a Varian 
Mercury 400 MHz NMR or Varian UnityINOVA 500 MHz NMR with VNMR 6.1C 
software. Chemical shift (8) values are reported in parts per million (ppm) relative to 
Me4Si (TMS) unless otherwise noted. X-ray crystallography was performed by Arnold L. 
Rheingold at the University of California, San Diego, La Jolla, California, USA, for 
compounds 14-18. UV-Vis data were taken at room temperature on a Varian 50 
Spectrophotometer. Electrochemistry was performed by Dr. Edward Wong using a 
Bioanalytical systems BAS 100B electrochemical work station with a glassy carbon 
working electrode, platinum wire auxiliary and silver /silver chloride reference electrode. 
Cyclic voltammograms were run at 200 mv/s. All solvents were reagent grade and were 
purified and dried as needed. All other reagents such as metal salts, drying agents, and 
alkylation material were obtained commercially and purified as needed as well. 
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4.2 Syntheses 
All reactions were performed under N2 atmosphere unless otherwise noted. 
Reactions above room temperature were run in flask using a condenser, oil bath, stir bar, 
and N2 inlet. All routine solvent evaporations were carried out with a rotary evaporator 
under reduced pressure and trace solvent removal was done using a vacuum pump. 
Hydrogen chloride ethanolic solution. HC1 gas was prepared from the reaction 
of solid sodium chloride (40.04 g) with concentrated sulfuric acid (50 mL). This gas was 
bubbled into absolute EtOH (50 mL) (Figure 4.1). Titration of the resulting HC1 
ethanolic solution with standardized aqueous NaOH gave the molarity of the total HC1 in 
solution. This stock solution was re-titrated before every use. 
Figure 4.1: General design for bubbling dry HC1 (gas) into absolute EtOH 
1,4,7-triazacyclononane (1). 1 was prepared in 74% yield by a published 
procedure.6,9'12'58'59 1,4,7-tritosyl-1,4,7-triazacyclononane (9.42 g, 15.90 mmol) in 
concentrated H2SO4 (85 mL) was heated and stirred for 84 hours at 100 °C. Solution was 
then allowed to cool at room temperature and placed into an ice bath to maintained the 
temperature below 10 °C. Cold absolute ethanol (85 mL) was added dropwise with 
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stirring and cooling followed by the addition of dry diethyl ether (130 mL). The formed 
precipitate was collected under N2 and dissolved in H 2 0 (15 mL). Solution was adjusted 
to a pH >14 with NaOH pellets and extracted with cold CHCI3 (7 x 40 mL). Portions of 
sodium chloride salt were added to the extraction funnel to increase the amount of 
extracted product. Chloroform extracts were dried with anhydrous Na2S04 and filtered. 
Filtrate was then evaporated to obtain yellowish oil. Further drying in vacuum line gave 
product as a white solid. (1.513 g, 11.71 mmol, 74%). The 'H and 13C{'H}NMR were 
consistent with the literature spectra. This compound was used without further 
purification. However, in some cases further purification using kugelrohr distillation 
(100 °C air bath temperature /100 millitorr) was required. 
l,4,7-triazatricyclo[5.2.1.04'10] decane (3). 3 was prepare in 82% yield following 
a literature procedure55"58'60'61 (Scheme 2.1). Using a short path distillation set up, TACN 
(1.01 g, 7.82 mmol) was combined with N,N-dimethylformamide dimethyl acetal (0.94 g, 
7.89 mmol) and stirred at 85 °C for 3 hours to obtain a brown-reddish solution. Crude 
material was cooled to room temperature and the byproducts of the reaction, MEOH and 
Me2NH, were removed under reduce pressure. Crude material was then purified by 
Kugelrohr (50 °C Air bath / 60 millitorr) yielding 0.89 g of colorless oil. JH NMR 
(CDCI3, 400 MHz) 8 (ppm) 2.75-2.85 (m, 6H, XX' of AA'XX'), 3.04-3.14 (m, 6H, AA' 
of AA'XX'), 5.04 (s, 1H). ^ C ^ H } NMR (CDCI3, 100.51 MHz) 8 (ppm) 52.11, 104.29. 
l-FormyI-l,4,7-triazacyclonane (4). 4 was prepared according to a literature 
procedure (Scheme 2.1).55'56'57 3 (910 mg, 6.51 mmol) were dissolved into 3 M HC1 (23 
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mL) and stirred at room temperature for 7 hours. Clear solution was placed into an ice-
water bath and a solution of cold 4 M NaOH (22 mL) was added dropwise or until pH 
was higher than 10. This aqueous solution was extracted with cold CHCI3 (8 x 40 mL). 
Chloroform extracts were dried with anhydrous Na2S04 and filtered out. Solvent was 
lastly evaporated to give 640 mg of white solid. A second extraction was performed to 
give 167 mg. 'H NMR (CDCI3, 400 MHz) 5 (ppm) 1.76 (s, 2H, #N-CH2CH2N/^), 2.71-
2.79 (m, 4H), 3.03-3.14 (m, 4H), 3.34-348 (m, 4H), 8.15 (s, 1H). ^ C ^ H } NMR (CDC13, 
100.51 MHz) <5 (ppm) 47.19, 48.78, 49.20, 49.88, 50.51, 53.14, 164.19. 
l-Formyl-l,4,7-triazacyclononane-4,7-diacetic acid diethyl ester (5). This 
ft) 
compound was reported in the literature but a different alkylation route was followed. 
Anhydrous sodium carbonate (194 mg, 1.83 mmol) and ethyl 2-bromoacetate were added 
to a solution of l-formyl-1,4,7 triazacyclononane (4) (141 mg, 0.900 mmol) in anhydrous 
acetonitrile (7.5 mL). The heterogeneous mixture was stirred under N2 atmosphere for 24 
hours at 55 °C. The mixture was allowed to cool at room temperature and solvent was 
evaporated. The flask with the residue was then placed in an ice-water bath and the 
residue was dissolved by the addition of cold 20% aq NaOH (8.5 mL). This aqueous 
solution was extracted with cold CHC13 (8 x 40 mL) and the combined extracts were 
dried over anhydrous Na2S04. Solvent was evaporated to give a yellowish oil (550 mg). 
The residue was chromatographed in ethyl acetate on a column of 50 grams of neutral 
alumina (M. Woelm, Eschwege, Germany) and eluted with same solvent (200 mL). The 
collected solvent was removed to give a clear oil (500 mg, 1.52 mmol, 88% yield). !H 
NMR (CDCI3, 400 MHz) 8 (ppm) 1.26-1.27 (t, 6H, C//5-CH2-0), 2.68, 2.76, 3.02, 3.24, 
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3.50 (6m, 6 x 2H, ring-NCJfc), 3.4 (s, 4H, N-C//2-COOEt), 4.17-4.18 (q, 4H, CH2-CH3), 
8.07 (s, 1H, N-CHO). "Cf 'H} NMR (CDC13, 100.51 MHz) 8 (ppm) 13.30 (CH3-CH2-
O), 46.11, 49.17 (ring-NCH2 next to the CHO), 52.93 and 56.64, 53.65 and 57.08 (ring-
NCH2), 53.87 and 57.11 (N-CH2-COOEt), 59.30 and 59.33 (CH3-CH2-0), 162.76 (CHO), 
170.78 and 170.96 (COO). 'H-NMR data were consistent with those reported by Kreher 
et al.,62 who prepared the compound from the precursor triazacyclononane orthoamide (3) 
rather than 1-formyl triazacyclononane (4). All chemical shifts from the "C l 'H} NMR 
spectrum were approximately one ppm up field than the reported shifts, although the 
number of resonances were consistent with the number of different carbons in the 
molecule. Additional characterization data were also acquired and consistent with the 
structure. ATR-IR 2909, 1735, 1663, 1443, 1415, 1370, 1183, 1134, 1059, 1027, 912 
cm"1; HR-MS-ESI-TOF, m/z (M+H)+ exact mass for Ci5H2gN305: 330.2023; Found: 
330.2007 (error -1.6 mmu/-4.9 ppm); m/z (M+Na)+ exact mass for Ci5H27N3Na05 : 
352.1843; Found: 352.1823 (error -2.0 mmu/-5.6 ppm). 
l,4,7-Triazacyclonane-4,7-diacetic acid diethyl ester • 2HC1 (6). The 
preparation of this compound was reported in the literature ; however a different and 
more selective approach was followed. A solution of 1-formyl-1,4,7-triazacyclononane-
1,4-diacetate diethyl ester (5) (500 mg, 1.52 mmol) in absolute EtOH (5 mL) was 
combined with a 2.05 M ethanolic solution of hydrogen chloride (see preparation above) 
(8.5 mL) and stirred at reflux for 24 hours. The cloudy yellowish solution was then 
allowed to cool down and the solvent was removed under reduced pressure to give an off-
white solid (562 mg). Absolute EtOH (8.0 mL) was added to the crude material and 
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heated in a water bath until clear; this solution was cooled down in cold water bath to 
obtain tiny white crystals. Solid was separated by filtration, washed with a small portion 
of cold EtOH, and dried under vacuum to obtain 255 mg of the product. The filtrate was 
transferred to a round-bottomed flask and solvent was evaporated to give off-white 
crystals. The recrystallization process was repeated two more times to yield an additional 
150 mg of the desired product for a total of 405 mg (1.08 mmol, 71% yield). 'H NMR 
(D20, 400 MHz) 5 1.27 (t, 6H, J = 7.2 Hz, -OCH2-C//3), 3.28 (s, 4H, ring-N-(C#2)2), 
3.36-3.55(m, 4x2H, ring-NC/^C/^NH), 3.95 (s, 4H, N-C/^-COOEt ), 4.25 (q, 2H, J = 
7.2 Hz,-OC//2-CH3 ); " C ^ H } NMR (D20, 100.51 MHz) 8 13.45 (CH3-CH2-0), 43.26, 
49.77, and 50.92 (ring-NCH2), 56.48 (N-CH2-COOEt), 63.04 (CH3-CH2-0); ATR-IR 
2924, 2534, 1738, 1434, 1290, 1247, 1202, 1174, 1118, 1096, 1051, 1010, 968 cm"1; 
Anal. Calcd. for C14H29C12N304.: C, 44.92; H, 7.81; N, 11.23; CI, 18.94 %. Found: 44.65, 
H, 7.91, N, 10.98, CI, 18.68%. ^C^HJNMR data were consistent with those reported by 
Van Haveren et al., who prepared the compound from the precursor 1,4,7 
triazacyclononane 1,4 diacetic acid (11). 
l,4,7-Triazacyclononane-acetamide-4,7-diacetic acid diethyl ester (7). 
Anhydrous potassium carbonate (250 mg, 1.81 mmol) was added to a solution of 1,4,7-
triazacyclonane-4,7-diacetic acid diethyl ester *2HC1 (6) (233 mg, 0.622 mmol) in dry 
acetonitrile (23 mL) and stirred at room temperature for 10 min. Then 2-bromoacetamide 
(117 mg, 0.848 mmol) was added to the reaction mixture and stirred for 20 hours at 50 
°C. At this point, the reaction mixture was cooled down to room temperature and the 
white insoluble salt was filtered out and washed with CH3CN. The combined filtrate was 
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evaporated and the residue was combined with cold aqueous solution of 4 M NaOH (13 
mL). The aqueous mixture was extracted with cold (0-5 °C) CHCI3 (7 * 40 mL) and the 
combined extracts were dried over anhydrous sodium sulfate. Solvent was then removed 
to give 194 mg, 87% yield of the desired compound as a yellowish oil. 'H NMR (CDCI3, 
400 MHz) 5 1.26 (t, 6H,-OCH2Ci/j), 2.62-2.70, 2.80-2.90 (2m, 4x2H, ring-NC/^C/^N-
amide), 2.84 (s, 4H, ring-N-C7/2CH2N-ester), 3.27 (s, 2H, 4H, N-Ctf2CONH2); 3.38 (s, 
4H, N-Ci/2-COOEt ), 4.15 (q, 4H, -OCi/2-CH3), 5.43 and 9.29 (s, 2H, N£Q; 
13C{'H}NMR (CHCI3, 100.51 MHz) 5 14.50 (-OCH2CH3), 55.41, 56.05, 58.42 (ring-
NCH2), 60.62 (N-CH2-COOEt ), 61.12 (N-CH2-CONH2), 172.04(CH2-COOEt), 176.44 
(CH2-CONH2); ATR-IR 3272, 2930, 2841, 1734, 1671, 1449, 1373, 1305, 1181, 1139, 
1114, 1063, 1026, 910 cm"1; HR-MS-ESI-TOF, m/z (M+H)+ exact mass for C16H31N4O5: 
359.2289; Found: 359.2283 (error -0.6 mmu/-1.7 ppm). 
Disodium-l,4,7-triazacyclononane-acetamide-4,7-diacetate (8) 1,4,7-
triazacyclononane acetamide-4,7-diacetic acid diethyl ester (24 mg, 0.067 mmol) was 
combined with 1M NaOD (0.2 mL) and D 2 0 (0.5 mL) and stirred at room temperature 
for 45 min to give a DzO solution of (8). NMR (D20, 400 MHz) 8 2.59-2.65, 3.23-
3.27, 3.38; 13C{1H}NMR (DzO, 100.51 MHz) 8 52.19, 60.43, 62.25, 178.09, 180.72. The 
solvent of this solution mixture was evaporated and the residue was re-dissolved in D20. 
NMR (D20, 400 MHz) 8 2.40-2.60, 3.04-3.29, 3.75; 13C{!H}NMR (D20, 100.51 
MHz) 8 51.10, 51.57, 51.64, 59.97, 61.40, 62.06, 177.64, 179.89, 180.70 (refer to pages 
32-33); ATR-IR 3300, 2807, 2841, 1679, 1583, 1406, 1335, 1291, 1258, 1121, 1054, 
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1011, 929 cm"1. Since NMR spectra was non reproducible, further studies and 
characterization data are required for fully characterization of compound (8). 
l-Formyl-l,4,7-triazacyclononane • copper(II) nitrate complex (13). Ligand 4 
(41 mg, 0.26 mmol) and copper nitrate 2.5 hydrate (61 mg, 0.26 mmol) were dissolved 
with absolute ethanol (5.5 mL each) in separate vials. The solutions were combined and 
a blue-lilac precipitate formed. The mixture was stirred at room temperature under N2 
atmosphere overnight. The precipitate formed was then centrifuged and washed with cold 
ethanol and ether. Residual solvent was removed to give (89 mg, 98%) of the blue-lilac 
solid. ATR-IR 3305, 3260, 1676, 1469, 1400, 1355, 1286, 1245, 1210, 1173, 1131, 1064, 
1085 cm"1; Anal. Calcd for CuCvHisNsO?: C, 24.39; H, 4.39; N, 20.31%. Found: C, 
24.67; H, 4.45; N, 20.13%. UV-Vis(H20) Xtaax= 661 nm (e - 46 M"1 cm"1). 
l-FormyI-1,4,7 triazacyclononane • zinc(II) nitrate complex (14). Ligand 4 
(40mg, 0.25mmol) in absolte EtOH was combined with a solution of zinc nitrate 
hexahydrated (77 mg, 0.26 mmol) in absolute ethanol to obtain a white precipitate 
instantaneously. This mixture was stirred at room temperature for 16 hours. The white 
precipitate was collected by centrifuging and this solid was washed with cold ethanol and 
ether. Solvent evaporation gave the white solid product (28 mg, 27% yield). X-ray quality 
crystals were obtained by suspending a sample in ethanol and ether and allowing it to 
stand for several days. 'H NMR (CDC13, 400 MHz) 5 2.90-2.95 and 3.04-3.09 (2m, 4H, 
ring-NGtf2Ci/2N-amine) 3.12-3.17 and 3.24-3.29 (2m, 4H, ring-N-Ci^CH2NCH=0), 
3.50-3.54 and 3.57-3.62 (2m, 4H, N-CH2C//2NCH=0); ATR-IR 3519, 3285, 2978, 
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1656, 1464, 1427, 1404, 1378, 1361, 1289, 1262, 1226, 1181, 1137, 1114, 1100, 1067 
l-Formyl-l,4,7-triazacyclononane-4-acetate-7-acetic acid ethyl ester • copper 
(II) chloride complex (15) To a solution of 1-formyl-1,4,7-triazacyclononane-4,7-
diacetic acid diethyl ester (5) (27 mg, 0.082 mmol) in absolute ethanol (2 mL) was added 
a light green solution of copper chloride dihydrate (14 mg, 0.085 mmol) in absolute 
ethanol (2 mL). The homogeneous green solution was stirred for 20 hours at room 
temperature. The solvent was evaporated and the residue was then re-dissolved in 
methanol and precipitated with the addition of ethyl acetate. The precipitate was 
centrifuged and washed with cold EtOH. Residual EtOH was removed in vacuo to yield 
the product as a green solid (26 mg). X-ray quality crystals were grown by slow diffusion 
of ethyl acetate into a solution of the crude material in MeOH. ATR-IR 2979, 2173, 
1980, 1732, 1714, 1646, 1490, 1453, 1407, 1344, 1298, 1222, 1107, 1039, 1017 cm"1; 
Anal. Calcd for CUC13H22N3O5CI (NaCl) (1.3CH3CH2OH): C, 36.19; H, 5.80; N, 8.12; 
CI, 13.70%. Found: C, 36.16; H, 5.73; N, 8.06; CI, 13.78%. UV-Vis(H20) Amax= 666 nm 
(e = 69 M"1 cm1). 
l,4,7-Triazacyclonane-4,7-diacetate diethyl ester • copper(II) chloride 
complex (16). l,4,7-triazacyclonane-4,7-diacetate diethyl ester • 2HC1 (16 mg, 0.043 
mmol) was dissolved with warm absolute ethanol (2 mL) and combined with a solution 
of cupric chloride dihydrate (7.6 mg, 0.045 mmol) in absolute EtOH (1 mL) and stirred 
at room temperature for 24 hours. Solvent was evaporated to give a light green solid, 
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which was then combined with a small amount of absolute EtOH and heated until clear. 
This solution was allowed to cool to room temperature and then placed in the refrigerator 
overnight. Tiny blue crystals were obtained, which were washed with cold ethanol, and 
dried under vacuum to give (18.5 mg 92% yield). X-ray quality crystals were obtained 
from cooling a hot ethanolic solution of the complex. ATR-IR 3466, 3248, 2979, 2927, 
1732, 1635, 1492, 1449, 1417, 1375, 1296, 1278, 1199, 1175, 1102, 1181, 1018 cm"1. 
Anal. Calcd. for CuCj4H27N304Cl2(0.5H20): C, 37.80; H, 6.34; N, 9.45; CI, 15.94 %. 
Found: C, 37.85; H, 6.33; N, 9.43; CI, 16.13 %. UV-Vis(H20) Xinax= 694 nm 
(e = 6 M"1 cm"1). 
l,4,7-Triazacyclononane-l-acetamide-4,7-diacetate diethyl ester • copper(II) 
•chloride complex (17). To a solution of l,4,7-triazacyclonane-l-acetamide-4,7-diacetate 
diethyl ester (23 mg, 0.064 mmol) (7) in ethanol (1 mL) a solution of cupric chloride 
dihydrate (11 mg, 0.064 mmol) in absolute EtOH (2 mL) was added dropwise and the 
reaction stirred at room temperature for 24 hours. Solvent was then evaporated and the 
residue was dissolved in a minimum amount of EtOH, ethyl acetate was added to induce 
precipitation. This precipitate was washed with a small amount of cold ethanol, separated 
by centrifuging, and dried under reduced pressure to yield light green crystals (24 mg, 
72% yield). X-ray quality crystals were obtained by slow evaporation of an acetonitrile 
solution of the complex. ATR-IR 2930, 1728, 1658, 1591, 1452, 1420, 1375, 1295, 1203, 
1180, 1098, 1053, 1018, 911 cm"1. Anal. Calcd. for CUC16H30N4O5CI2 
(0.3NaCl)(0.7H20): C, 36.74; H, 6.05; N, 10.71; CI, 15.59 %. Found: C, 36.52; H, 6.05; 
N, 10.36; CI, 15.51%. UV-Vis (HzO) Km = 716 nm (e = 57 M"1 cm"1). 
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l,4,7-Triazacyclononane-l-acetamide-4,7-diacetate • copper(II) complex (18). 
l,4,7-triazacyclononane-l-acetamide-4,7-diacetate-diethyl ester (7) (16.5 mg, 0.046 
mmol) was combined with deionized (D.I.) water (0.5mL) and 1M aqueous NaOH (0.2 
mL). This mixture was stirred until clear. A solution of copper chloride dihydrate (7.9 
mg, 0.046 mmol) in D.I. water (1 mL) was added to give a blue solution. The pH of the 
final solution was adjusted to approximately 7 with 1 M NaOH. This was stirred at room 
temperature overnight to give a dark blue solution which was then evaporated to dryness 
under reduced pressure. The residue was treated with absolute ethanol and a light blue 
insoluble material was separated by centrifuging. This supernatant was dried under 
reduced pressure to give small dark-blue crystals (14 mg) 45% yield. X-ray quality 
crystals were grown from cooling a sample in a hot ethanolic solution containing a few 
drops of D.I. water. ATR-IR 3450, 3305, 1652, 1605, 1491, 1346, 1322, 1302, 1289, 
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